NEW YORK (GenomeWeb News) – Gene Logic today said it will try to discover new development paths for drug candidates discontinued in clinical trials by Eli Lilly.
 
The candidates were discontinued for reasons other than safety, Gene Logic said.
 
Under the deal, Gene Logic has the option to receive an exclusive license to any drug candidate Eli Lilly decides not to purse. Eli Lilly would receive success-based milestone and royalty payments on those candidates.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.